B12
Global tests
Type III ANOVA on main and interaction effects, and LM model summaries.
PRL (ng/ml)
|
|
Chisq
|
Df
|
Pr(>Chisq)
|
|
|
(Intercept)
|
113.7952111
|
1
|
<0.0001
|
***
|
|
B12
|
0.0039381
|
1
|
0.9
|
ns
|
|
Study
|
0.1835478
|
1
|
0.7
|
ns
|
|
GA_samp
|
132.0512503
|
1
|
<0.0001
|
***
|
|
B12:Study
|
0.4161577
|
1
|
0.5
|
ns
|
hPL (μg/ml)
|
|
Chisq
|
Df
|
Pr(>Chisq)
|
|
|
(Intercept)
|
24.428879
|
1
|
<0.0001
|
***
|
|
B12
|
1.133261
|
1
|
0.3
|
ns
|
|
Study
|
3.998083
|
1
|
0.05
|
ns
|
|
GA_samp
|
1648.072726
|
1
|
<0.0001
|
***
|
|
B12:Study
|
0.017806
|
1
|
0.9
|
ns
|
GH2 (ng/ml)
|
|
Chisq
|
Df
|
Pr(>Chisq)
|
|
|
(Intercept)
|
336.340208
|
1
|
<0.0001
|
***
|
|
B12
|
6.624419
|
1
|
0.01
|
*
|
|
Study
|
1.872150
|
1
|
0.2
|
ns
|
|
GA_samp
|
815.254269
|
1
|
<0.0001
|
***
|
|
B12:Study
|
1.840691
|
1
|
0.2
|
ns
|
Insulin (uU/ml)
|
|
model term
|
df1
|
df2
|
F.ratio
|
Chisq
|
p.value
|
|
|
1
|
B12
|
1
|
Inf
|
4.297
|
4.297
|
0.04
|
*
|
|
3
|
Study
|
1
|
Inf
|
7.878
|
7.878
|
0.005
|
**
|
|
4
|
GA_samp
|
1
|
Inf
|
0.122
|
0.122
|
0.7
|
ns
|
|
2
|
B12:Study
|
1
|
Inf
|
1.131
|
1.131
|
0.3
|
ns
|
HOMA-IR
|
|
model term
|
df1
|
df2
|
F.ratio
|
Chisq
|
p.value
|
|
|
1
|
B12
|
1
|
Inf
|
3.806
|
3.806
|
0.05
|
ns
|
|
3
|
Study
|
1
|
Inf
|
11.788
|
11.788
|
0.0006
|
***
|
|
4
|
GA_samp
|
1
|
Inf
|
0.209
|
0.209
|
0.6
|
ns
|
|
2
|
B12:Study
|
1
|
Inf
|
1.079
|
1.079
|
0.3
|
ns
|
Glucose (mmol/L)
|
|
model term
|
df1
|
df2
|
F.ratio
|
Chisq
|
p.value
|
|
|
1
|
B12
|
1
|
Inf
|
2.841
|
2.841
|
0.09
|
ns
|
|
3
|
Study
|
1
|
Inf
|
30.734
|
30.734
|
<0.0001
|
***
|
|
4
|
GA_samp
|
1
|
Inf
|
0.333
|
0.333
|
0.6
|
ns
|
|
2
|
B12:Study
|
1
|
Inf
|
0.595
|
0.595
|
0.4
|
ns
|
Model summary
Ratio of Geometric means (95% CI)
PRL (ng/ml)
|
Var
|
Effect
|
P
|
|
(Intercept)
|
12.05 (7.69, 18.87)
|
<0.0001
|
|
B12
|
1.00 (1.00, 1.00)
|
0.41
|
|
StudySTOP
|
1.01 (0.88, 1.16)
|
0.87
|
|
GA_samp
|
1.17 (1.14, 1.20)
|
<0.0001
|
hPL (μg/ml)
|
Var
|
Effect
|
P
|
|
(Intercept)
|
1.81 (1.44, 2.28)
|
<0.0001
|
|
B12
|
1.00 (1.00, 1.00)
|
0.04
|
|
StudySTOP
|
1.14 (1.06, 1.22)
|
0.0003
|
|
GA_samp
|
1.34 (1.32, 1.36)
|
<0.0001
|
GH2 (ng/ml)
|
Var
|
Effect
|
P
|
|
(Intercept)
|
0.06 (0.04, 0.08)
|
<0.0001
|
|
B12
|
1.00 (1.00, 1.00)
|
0.01
|
|
StudySTOP
|
1.02 (0.93, 1.12)
|
0.66
|
|
GA_samp
|
1.32 (1.29, 1.34)
|
<0.0001
|
Insulin (uU/ml)
|
Var
|
Effect
|
P
|
|
(Intercept)
|
18.19 (9.98, 33.15)
|
<0.0001
|
|
B12
|
1.00 (1.00, 1.00)
|
0.04
|
|
StudySTOP
|
0.72 (0.60, 0.86)
|
0.0003
|
|
GA_samp
|
0.99 (0.96, 1.03)
|
0.71
|
HOMA-IR
|
Var
|
Effect
|
P
|
|
(Intercept)
|
4.54 (2.43, 8.49)
|
<0.0001
|
|
B12
|
1.00 (1.00, 1.00)
|
0.06
|
|
StudySTOP
|
0.62 (0.51, 0.75)
|
<0.0001
|
|
GA_samp
|
0.99 (0.95, 1.03)
|
0.63
|
Glucose (mmol/L)
|
Var
|
Effect
|
P
|
|
(Intercept)
|
5.67 (5.09, 6.31)
|
<0.0001
|
|
B12
|
1.00 (1.00, 1.00)
|
0.10
|
|
StudySTOP
|
0.87 (0.84, 0.90)
|
<0.0001
|
|
GA_samp
|
1.00 (0.99, 1.00)
|
0.57
|
Estimated means
Estimated marginal means (or adjusted means) adjusted for GA at sampling.
Results are averaged over the levels of B12 concentration (pM) and may be misleading when interaction term is involved.
PRL (ng/ml)
|
Study
|
response
|
SE
|
df
|
lower.CL
|
upper.CL
|
|
SCOPE
|
96.44883
|
7.991495
|
103.34357
|
81.83386
|
113.6739
|
|
STOP
|
97.57641
|
7.546418
|
78.86473
|
83.65432
|
113.8155
|
hPL (μg/ml)
|
Study
|
response
|
SE
|
df
|
lower.CL
|
upper.CL
|
|
SCOPE
|
90.37671
|
2.675871
|
190.0294
|
85.24966
|
95.81211
|
|
STOP
|
102.98997
|
2.681540
|
114.0150
|
97.81254
|
108.44145
|
GH2 (ng/ml)
|
Study
|
response
|
SE
|
df
|
lower.CL
|
upper.CL
|
|
SCOPE
|
2.305636
|
0.0775524
|
424.6029
|
2.158132
|
2.463223
|
|
STOP
|
2.354790
|
0.0636642
|
207.0318
|
2.232563
|
2.483709
|
Insulin (uU/ml)
|
Study
|
response
|
SE
|
df
|
asymp.LCL
|
asymp.UCL
|
|
SCOPE
|
14.15732
|
0.8882227
|
Inf
|
12.519214
|
16.00976
|
|
STOP
|
10.17033
|
0.4597934
|
Inf
|
9.307926
|
11.11264
|
HOMA-IR
|
Study
|
response
|
SE
|
df
|
asymp.LCL
|
asymp.UCL
|
|
SCOPE
|
3.420104
|
0.2279209
|
Inf
|
3.001332
|
3.897308
|
|
STOP
|
2.123460
|
0.1003240
|
Inf
|
1.935658
|
2.329483
|
Glucose (mmol/L)
|
Study
|
response
|
SE
|
df
|
asymp.LCL
|
asymp.UCL
|
|
SCOPE
|
5.406117
|
0.0673630
|
Inf
|
5.275688
|
5.539772
|
|
STOP
|
4.711955
|
0.0397875
|
Inf
|
4.634615
|
4.790586
|
Comparisons
Effect for every 100 unit increase in B12 concentration (pM).
|
Hormone
|
Contrast
|
Study
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
PRL (ng/ml)
|
B12363.5 / B12263.5
|
SCOPE
|
1.01 (0.98, 1.05)
|
0.4
|
|
PRL (ng/ml)
|
B12363.5 / B12263.5
|
STOP
|
1.01 (0.98, 1.05)
|
0.4
|
|
hPL (μg/ml)
|
B12363.5 / B12263.5
|
SCOPE
|
1.02 (1.00, 1.04)
|
0.04
|
|
hPL (μg/ml)
|
B12363.5 / B12263.5
|
STOP
|
1.02 (1.00, 1.04)
|
0.04
|
|
GH2 (ng/ml)
|
B12363.5 / B12263.5
|
SCOPE
|
1.03 (1.01, 1.05)
|
0.01
|
|
GH2 (ng/ml)
|
B12363.5 / B12263.5
|
STOP
|
1.03 (1.01, 1.05)
|
0.01
|
|
Insulin (uU/ml)
|
B12363.5 / B12263.5
|
SCOPE
|
0.95 (0.91, 1.00)
|
0.04
|
|
Insulin (uU/ml)
|
B12363.5 / B12263.5
|
STOP
|
0.95 (0.91, 1.00)
|
0.04
|
|
HOMA-IR
|
B12363.5 / B12263.5
|
SCOPE
|
0.95 (0.90, 1.00)
|
0.06
|
|
HOMA-IR
|
B12363.5 / B12263.5
|
STOP
|
0.95 (0.90, 1.00)
|
0.06
|
|
Glucose (mmol/L)
|
B12363.5 / B12263.5
|
SCOPE
|
0.99 (0.99, 1.00)
|
0.10
|
|
Glucose (mmol/L)
|
B12363.5 / B12263.5
|
STOP
|
0.99 (0.99, 1.00)
|
0.10
|
Estimated means (50 unit increase)
Estimated marginal means (or adjusted means) adjusted for GA at sampling.
Results are averaged over the levels of B12 concentration (pM) and may be misleading when interaction term is involved.
PRL (ng/ml)
|
Study
|
response
|
SE
|
df
|
lower.CL
|
upper.CL
|
|
SCOPE
|
96.12350
|
7.943488
|
102.26730
|
81.59159
|
113.2436
|
|
STOP
|
97.24727
|
7.514380
|
78.60051
|
83.38271
|
113.4172
|
hPL (μg/ml)
|
Study
|
response
|
SE
|
df
|
lower.CL
|
upper.CL
|
|
SCOPE
|
89.98138
|
2.648226
|
185.8123
|
84.90570
|
95.36048
|
|
STOP
|
102.53947
|
2.664550
|
113.1569
|
97.39417
|
107.95658
|
GH2 (ng/ml)
|
Study
|
response
|
SE
|
df
|
lower.CL
|
upper.CL
|
|
SCOPE
|
2.288290
|
0.0761590
|
410.6529
|
2.143372
|
2.443006
|
|
STOP
|
2.337074
|
0.0630674
|
206.3572
|
2.215985
|
2.464780
|
Insulin (uU/ml)
|
Study
|
response
|
SE
|
df
|
asymp.LCL
|
asymp.UCL
|
|
SCOPE
|
14.33738
|
0.8943328
|
Inf
|
12.687433
|
16.20189
|
|
STOP
|
10.29968
|
0.4592552
|
Inf
|
9.437771
|
11.24031
|
HOMA-IR
|
Study
|
response
|
SE
|
df
|
asymp.LCL
|
asymp.UCL
|
|
SCOPE
|
3.463888
|
0.2293611
|
Inf
|
3.042297
|
3.943901
|
|
STOP
|
2.150644
|
0.1002700
|
Inf
|
1.962830
|
2.356429
|
Glucose (mmol/L)
|
Study
|
response
|
SE
|
df
|
asymp.LCL
|
asymp.UCL
|
|
SCOPE
|
5.415384
|
0.0667619
|
Inf
|
5.286101
|
5.547829
|
|
STOP
|
4.720032
|
0.0401342
|
Inf
|
4.642022
|
4.799353
|
Comparisons (50 unit increase)
Effect for every 50 unit increase in B12 concentration (pM).
|
Hormone
|
Contrast
|
Study
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
PRL (ng/ml)
|
B12313.5 / B12263.5
|
SCOPE
|
1.01 (0.99, 1.02)
|
0.4
|
|
PRL (ng/ml)
|
B12313.5 / B12263.5
|
STOP
|
1.01 (0.99, 1.02)
|
0.4
|
|
hPL (μg/ml)
|
B12313.5 / B12263.5
|
SCOPE
|
1.01 (1.00, 1.02)
|
0.04
|
|
hPL (μg/ml)
|
B12313.5 / B12263.5
|
STOP
|
1.01 (1.00, 1.02)
|
0.04
|
|
GH2 (ng/ml)
|
B12313.5 / B12263.5
|
SCOPE
|
1.02 (1.00, 1.03)
|
0.01
|
|
GH2 (ng/ml)
|
B12313.5 / B12263.5
|
STOP
|
1.02 (1.00, 1.03)
|
0.01
|
|
Insulin (uU/ml)
|
B12313.5 / B12263.5
|
SCOPE
|
0.98 (0.95, 1.00)
|
0.04
|
|
Insulin (uU/ml)
|
B12313.5 / B12263.5
|
STOP
|
0.98 (0.95, 1.00)
|
0.04
|
|
HOMA-IR
|
B12313.5 / B12263.5
|
SCOPE
|
0.97 (0.95, 1.00)
|
0.06
|
|
HOMA-IR
|
B12313.5 / B12263.5
|
STOP
|
0.97 (0.95, 1.00)
|
0.06
|
|
Glucose (mmol/L)
|
B12313.5 / B12263.5
|
SCOPE
|
1.00 (0.99, 1.00)
|
0.10
|
|
Glucose (mmol/L)
|
B12313.5 / B12263.5
|
STOP
|
1.00 (0.99, 1.00)
|
0.10
|
Diagnostics
Model diagnositcs.
Diagnositcs for PRL (ng/ml)
Diagnositcs for hPL (μg/ml)
Diagnositcs for GH2 (ng/ml)
Diagnositcs for Insulin (uU/ml)
Diagnositcs for HOMA-IR
Diagnositcs for Glucose (mmol/L)
